ASP Calculation Rankles IG; Drugs To Face Dropping Reimbursement Rates?
The HHS Office of Inspector General is dissatisfied with the CMS' response to an OIG report showing that comparison of a Part B-reimbursed drug's average sales price (ASP) with its average manufacturer price (AMP) yields different results based on the calculation method used
You may also be interested in...
The HHS Office of Inspector General (OIG) contends that reimbursement for five Medicare Part B drugs is too high relative to their market prices and recommends that CMS lower payment levels for them
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011